Abbott Beats Second-Quarter Profit and Sales Estimates and Raises Full-Year Outlook on $12.6 Billion Revenue

businesscompany-earnings 3 posts · 2 accounts

Abbott posted second-quarter sales of $12.59 billion and adjusted earnings of $1.31 a share, beating analyst estimates and leading the medical products maker to raise its full-year profit outlook.

The beat was supported by a 13% year-over-year revenue increase, with diagnostics sales surging 42% to $3.09 billion. Management said the second-quarter results reflect building momentum it expects to accelerate in the second half of the year. Abbott reaffirmed full-year comparable sales growth of 6.5% to 7.5% and lifted its full-year adjusted EPS guidance to a range of $5.45 to $5.60, up from $5.38 to $5.58.

From the sources (3 posts)

@wallstengine

ABBOTT $ABT Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $12.59B (Est. $12.48B) 🟢; +13.0% YoY 🔹 Adj. EPS: $1.31 (Est. $1.28) 🟢; +4.0% YoY 🔹 Diagnostics Rev: $3.09B; +42.3% YoY FY26 Guide: 🔹 Adj. EPS: $5.45-$5.60; raised from $5.38-$5.58 🟢 🔹 Comp

@firstsquawk

Abbott Labs Q2 2026 Earnings - Adj EPS $1.31 (est $1.276) - FY Adj EPS Sees $5.45 To $5.60, Saw $5.38 To $5.58 - Comp Sales +4.8% - Net Sales $12.59B (est $12.54B)

@firstsquawk

ABBOTT Q2 SALES $12.6 BLN VS IBES ESTIMATE $12.50 BLN || OUTLOOK FY SALES GROWTH 6.5% TO 7.5% ||

Johnson & Johnson Raises Full-Year Guidance on Second-Quarter Profit of $2.90 Per Share and $25.3 Billion in Sales GE Aerospace Beats Second-Quarter Earnings Estimates to Post $2.02 Profit, Raises Full-Year Guidance